Xconomy

AUGUST 31, 2016

Roger Tsien, a UC San Diego scientist who shared the 2008 Nobel Prize in chemistry for research that led to the development of fluorescent proteins used to illuminate tissue and track biological processes, has died, according to a statement from the university. He compared himself to John C.

San Diego 72

San Diego UCSD Avalon Study 72

Xconomy

DECEMBER 20, 2018

New biopharma company Aristea Therapeutics has raised $15 million from Novo Holdings, the Danish investment company, and secured global rights to an investigational AstraZeneca drug that’s ready for Phase 2 study. The San Diego, CA, company made its public debut this week after starting up quietly earlier this year.

Develop 67

Develop Development San Diego Study 67

Xconomy

JUNE 23, 2020

Reneo Pharmaceuticals has encouraging results from an early trial of a compound it is advancing for rare diseases characterized by impaired mitochondria—our cells’ energy generators—and the company says it is now designing a large global study of its drug candidate.

San Diego 127

San Diego Study Design Develop 127

Xconomy

APRIL 7, 2020

Inovio Pharmaceuticals, one of the biotechs developing a vaccine to prevent COVID-19, has received the FDA’s OK to start testing its candidate in healthy volunteers. The Plymouth Meeting, PA-based company, which also conducts research in San Diego, plans to enroll as many as 40 adults across two trial locations.

San Diego 108

San Diego Study Research Develop 108

Xconomy

SEPTEMBER 15, 2016

The Connect Innovation Report found that 405 software, technology, and life sciences startups were created last year in San Diego County. Software startups made up nearly 63 percent (255 companies created) of all new high-tech ventures created in 2015, a trend fueled chiefly by software app development, according to the report.

San Diego 40

San Diego Report High Tech Study 40

Xconomy

MARCH 28, 2019

million from new investors, including the New York-based Juvenile Diabetes Research Foundation, following the results of a clinical study of its experimental biomarker monitoring device. Founders Jared Tagney and Joshua Windmiller, who met while in grad school at UC San Diego, started the company in 2012 as Electrozyme.

San Diego 103

San Diego Study Research Design 103

Xconomy

DECEMBER 18, 2019

More than 250 miles above the Earth’s surface aboard the International Space Station, a first-in-kind study of neurodegenerative disease is expected to reveal never-before-seen cell interactions.

Research 90

Research San Diego Study Funding 90

Xconomy

JULY 2, 2018

The test, sold by Genomic Health (NASDAQ: GHDX ) of Redwood City, CA, and developed by Epic Sciences of San Diego, is for men with a dangerous, Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

Guide 81

Guide Study San Diego Journal 81

Xconomy

OCTOBER 13, 2020

Gossamer Bio’s lead drug, an experimental treatment for asthma and allergies, has failed in two mid-stage clinical trials but the biotech sees enough in the data to pursue further development in a severe form of asthma and it wants to talk with regulators about advancing the compound to a larger Phase 3 study.

San Diego 82

San Diego Study Develop Development 82

Xconomy

NOVEMBER 11, 2019

A Roche drug in development as a treatment for spinal muscular atrophy achieved the main goals of a key study, helping to build the case that the drug could challenge a Biogen therapy already approved for the rare disorder. The Basel, Switzerland-based company plans to present full data from the study at a future medical conference.

Study 49

Study Conference Help Develop 49

Xconomy

FEBRUARY 26, 2020

About three years ago fledgling San Diego-based startup PvP Biologics announced a $35 million deal with Takeda Pharmaceutical that gave the Japan pharma giant rights to acquire the company down the line. The deal follows completion of a Phase 1 study evaluating the PvP drug. That day is here.

San Diego 72

San Diego Study Develop Development 72

Xconomy

APRIL 22, 2019

Swiss pharma giant Novartis has invested $75 million in a $142 million Series C round for San Diego-based Poseida, which is one of several companies developing what is meant to be a one-time, long-lasting treatment for multiple myeloma. Multiple myeloma affects about 300,000 Americans every year.

San Diego 83

San Diego Study Funding Invest 83

Xconomy

MAY 5, 2020

Kura Oncology is discontinuing development of one of its three clinical-stage cancer drug candidates amid pandemic-related impacts to its clinical trial plans. The company had recently landed on a recommended Phase 2 dose of KO-947, and was preparing to test it in patients with head and neck squamous cell.

San Diego 63

San Diego Study Develop Development 63

Xconomy

AUGUST 22, 2019

Retrophin, the drug developer founded by jailed former biotech executive Martin Shkreli, has failed its first big test. The San Diego-based company’s experimental drug fosmetpantotenate failed a Phase 3 trial, FORT, in patients with a rare and deadly neurological disorder called pantothenate kinase-associated neurodegeneration, or PKAN.

San Diego 79

San Diego Study Marketing Develop 79

Xconomy

OCTOBER 1, 2018

VelosBio joined Johnson & Johnson’s JLABS @ San Diego incubator in January. The company is developing antibody drug conjugates, a class of cancer drug that links antibodies to potent cancer-fighting toxins. The new VelosBio cash is earmarked for completing the work needed to proceed into human studies.

San Diego 91

San Diego Incubator Class Study 91

Xconomy

JULY 6, 2016

The Obama administration’s push to sign up one million Americans for a long-term health study will start in New York, Pittsburgh, Chicago, and Tucson, AZ, top health officials said today. The VA is running its own long-term study with nearly half a million participants so far.).

Study 59

Study PMI San Diego Sample 59

Xconomy

APRIL 11, 2017

As part of the financing, Kalamazoo-based Octeta Therapeutics has been rechristened Cirius Therapeutics, and three San Diego-based biotech executives are stepping into key executive roles. All three were former Laguna Pharmaceuticals executives who spent the past 16 months scouting for Frazier as entrepreneurs-in-residence.

Study 55

Study San Diego Entrepreneur Venture Capital 55

Xconomy

SEPTEMBER 9, 2019

Based on the results, the San Diego company said it would end the study early and seek a meeting with the regulator to discuss filing next year for approval in dementia-related psychosis. Pimavanserin was approved in 2016 as a treatment for psychosis associated with.

San Diego 74

San Diego Study Report Company 74

Xconomy

NOVEMBER 3, 2017

Klotho Therapeutics , a virtual biotech developing a kidney disease treatment based on its proprietary engineered version of the human klotho enzyme, said Thursday it has raised $10 million in Series A financing from San Diego’s Thynk Capital. Studies in mice have.

San Diego 85

San Diego Study Capital Technology 85

Xconomy

AUGUST 22, 2016

In downtown San Diego, a private real estate company best known for its master-planned communities in suburban Southern California has posed some existential questions for regional tech hubs looking to build their own startup ecosystems. 101 West Broadway tower in downtown San Diego.

Develop 40

Develop Development San Diego Startup 40

Xconomy

APRIL 18, 2018

John Dobak, a life sciences serial entrepreneur in San Diego, said a new startup he’s leading has raised $2.66 The biotech, 10xBio, announced earlier this month that the FDA had approved its application to begin clinical trials in Phase 1b/2a studies testing the unnamed injectable drug.

San Diego 72

San Diego Study Entrepreneur Startup 72

Xconomy

FEBRUARY 15, 2017

Liver disease is challenging for doctors because it can develop without symptoms, making diagnosis difficult without removing cells for examination. For these reasons, fatty liver disease is often called a “silent disease,” says Ariel Feldstein, a gastroenterologist at the University of California San Diego.

UCSD 64

UCSD Press San Diego Class 64

Xconomy

SEPTEMBER 30, 2020

Ovid Therapeutics and Takeda Pharmaceutical joined forces three years ago to develop a small molecule into a potential epilepsy drug. That research is starting to pay off as the companies now look ahead to pivotal studies testing that compound in several inherited forms of the disorder.

Statistics 111

Statistics Study Report Research 111

Xconomy

DECEMBER 7, 2017

Metacrine , a biotech developing new drugs for treating chronic liver diseases and related metabolic diseases and disorders, said today it has raised $22 million in a Series B financing led by New Enterprise Associates, a new investor. Initial studies should be completed by the end of the year, the San Diego-based company said.

San Diego 49

San Diego Study Develop Development 49

Xconomy

NOVEMBER 4, 2019

An experimental Halozyme Therapeutics treatment for pancreatic cancer has failed a pivotal study, and the company is stopping further development of the drug and closing its oncology operations as part of a corporate restructuring.

San Diego 40

San Diego Study Develop Development 40

Xconomy

JUNE 19, 2019

Cancer immunotherapies have shown to be effective as a treatment for some cancers, but only in a fraction of patients. Oncolytics, which. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

Study 61

Study Activity Develop Development 61

Xconomy

JUNE 11, 2020

The study, set to begin next month, is targeting enrollment of about 30,000 volunteers, Moderna (NASDAQ: MRNA ) announced Thursday. The main goal of the study will be preventing the symptoms of COVID-19 disease. Those patients will be randomly assigned to receive either the vaccine candidate, mRNA-1273, or a placebo.

Study 101

Study Report San Diego Research 101

Xconomy

FEBRUARY 19, 2019

But they are nonetheless expected by the drug’s developer, Intercept Pharmaceuticals, to be good enough to support approval. Intercept (NASDAQ: ICPT ) this morning provided an interim look at a 2,370-patient NASH study known as REGENERATE.

Study 109

Study Help Marketing Develop 109

Xconomy

OCTOBER 5, 2016

San Diego-based Organovo (NASDAQ: ONVO ) said today it plans to use its 3D bio-printing technology to produce living human liver tissue “patches” that can be transplanted in patients with fatal liver disease. liver transplant waiting list. liver transplant waiting list.

San Diego 105

San Diego Outsource Development Study Sample 105

Xconomy

DECEMBER 17, 2018

It can take decades and billions of dollars to develop a drug, and its fate—and often that of its developer—rests in the outcome of clinical trials. The failure of a closely-watched cancer immunotherapy combination sent ripples through the sector and led several companies to change development strategies.

Study 95

Study Develop Development San Diego 95

Xconomy

NOVEMBER 2, 2018

The gene-editing technology CRISPR-Cas9 is opening up new research avenues all the time, such as giving drug developers a cheaper, faster way to knock out genes in tumor cells. Studies of CRISPR-Cas9 to treat human disease are about to start, too. This week, we reported on a new study that raises exactly that question.

Study 74

Study Startup Research Report 74

Xconomy

APRIL 9, 2020

These studies could begin as early as the end of April, assuming the companies receive regulatory clearance. The partnership pairs the mRNA vaccine technology of BioNTech (NASDAQ: BNTX ) with the vaccine and clinical trial experience of Pfizer (NYSE: PFE ).

Study 122

Study Sites Technology San Diego 122

Xconomy

FEBRUARY 27, 2017

San Diego-based La Jolla (NASDAQ: LJPC ) is studying its drug LJPC-501 in patients who have dangerously low blood pressure, which can lead to distributed shock, a condition in which tissues and organs don’t receive adequate blood flow.

San Diego 40

San Diego Study Pricing Organization 40

Xconomy

DECEMBER 20, 2016

An Acadia Pharmaceuticals drug developed to treat hallucinations and delusions experienced by Parkinson’s disease patients is now showing signs it could also treat similar psychoses associated with Alzheimer’s disease.

San Diego 40

San Diego Statistics Study News 40

Xconomy

SEPTEMBER 2, 2016

Nobel Prize winner Roger Tsien, a UC San Diego chemist, passed away in Oregon this week. As the San Diego Union Tribune reported in 2013, Tsien (pictured) was also unafraid to shine the spotlight on what he considered suspect scientific approaches, even when espoused by legends like DNA co-discoverer James Watson.

News 57

News San Diego Journal Technical Review 57

Xconomy

JULY 22, 2019

Acadia Pharmaceuticals’ treatment for Parkinson’s disease-related psychosis failed a Phase 3 trial that was studying use of the drug for schizophrenia patients who haven’t fully responded to existing therapies. The company announced the trial failure Monday after market close.

Study 80

Study News Marketing San Diego 80

Xconomy

APRIL 20, 2017

San Antonio — George Perry, a scientist at the University of Texas at San Antonio, has long proposed that drug developers and researchers need to look earlier into the roots of Alzheimer’s disease. A potential discovery that targets the early development of the disease—in.

Study 68

Study Research Develop Development 68